FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379522799> ?p ?o ?g. }

• W4379522799 endingPage "337" @default.
• W4379522799 startingPage "336" @default.
• W4379522799 abstract "Background Conventional disease-modifying anti-rheumatic drugs (cDMARDs) are recommended in addition to glucocorticoids (GC) for all active Takayasu’s arteritis (TAK) patients as the first-line therapy.However, there is limited data comparing cDMARDs as the first-line immunosuppressive (IS) treatment. Objectives In this study, we aimed to compare the outcomes of methotrexate (MTX) and azathioprine (AZA), which were used most frequently as the first-line cDMARDs in TAK patients. Methods TAK patients who received cDMARDs in addition to GCs as the initial therapy were included in this multicenter retrospective cohort study. Clinical, laboratory and imaging data of the patients were assessed. In addition, a match analysis (cc match) using variables ‘age’, ‘gender’ and ‘diffuse aortic involvement’ was performed between patients who received MTX or AZA as first-line cDMARD treatment. Results We included 301 (F/M: 260/41, mean age: 42.2±13.3) patients from 10 centres in the study. As the first-line cDMARD, 204 (67.8%) patients received MTX and 77 (25.6%) patients received AZA. First cDMARD was cyclophosphamide in 17 (5.6%), leflunomide in 2 (0.5%) and mycophenolate mofetil in one patient. The remission, relapse and radiographic progression rates were similar between patients who received MTX and AZA as first-line cDMARDs. Vascular surgery rate was higher in the AZA (23% vs. 9%, p=0.001), whereas the frequency of patients receiving ≤5 mg/day GCs at the end of the follow-up was higher in the MTX group (76 vs 62%, p=0.034). Similarly, the rate of vascular surgery was higher and the GC dose reduction rate (≤5 mg) was lower in AZA group in match analysis. Drug survival was similar between MTX and AZA groups (median 48 months, MTX vs AZA: 32% vs 42%, p=0.34). IS therapy was discontinued in 18 (11 MTX, 7 AZA) patients during the follow-up period due to remission. In the IS discontinuation group 2 patients had a relapse at 2 and 6 months, while 16 patients were still on remission at the end of mean 69.4 (±50.9) months of follow-up. Conclusion Remission, relapse, radiographic progression and drug survival rates of azathioprine and methotrexate were similar in Takayasu’s arteritis patients having the first-line of therapy. The rate of vascular surgery was higher and the rate of steroid dose reduction was lower with azathioprine compared to methotrexate at the end of the follow-up. Table 1. Demographic and clinical characteristics of patients with Takayasu’s arteritis Total group (n=301) First-line methotrexate (n=204) First-line azathioprine (n=77) p Age, mean±SD 42,2±13,3 43,5±13,3 40,4±13,2 0,08 Gender, female, n(%) 260 (86) 184 (90) 63 (82) 0,055 Duration of first cDMARD, months 35 (3-336) 35,5 (3-312) 35 (3-336) 0,64 Remission with first cDMARD, n(%) 193/296 (65) 138/199 (69) 50/77 (65) 0,48 Disease activity (baseline ) PGA, active, n (%) 283/297 (95) 191/201 (95) 74/77 (96) 0,70 Kerr, active, n (%) 270/289 (93) 181/195 (93) 70/75 (93) 0,53 ITAS 2010 9 (2-20) 9 (0-19) 10 (3-21) 0,61 Disease activity (12th month) PGA, active, n (%) 53/118 (45) 33/76 (43) 18/39 (46) 0,78 Kerr, active, n (%) 32/120 (27) 24/79 (30) 6/38 (16) 0,26 ITAS 2010 1 (0-11) 1 (0-9) 1 (0-11) 0,48 Relapse rate, n(%) 95/192 (50) 68/138 (49) 24/49 (49) 0,97 Vascular surgery rate with first cDMARD, n(%) 40/291 (14) 17/196 (9) 18/77 (23) 0,001 GC dose reduction (≤5 mg) or discontinuation with first cDMARD, n(%) 153/220 (70) 110/145 (76) 100/65 (62) 0,034 Radiographic progression, n(%) 75/142 (53) 48/98 (49) 22/39 (56) 0,43 CRP, baseline, mg/L 13 (0,4-235) 15,3 (0,5-280) 19,0 (0,4-145) 0,82 CRP, 12th month, mg/L 3 (0,8-130) 4,4 (0,2-200) 3,7(0,4-83) 0,90 Figure 1. Drug survival for methotrexate and azathioprine treatments in TAK patients as first-line cDMARD REFERENCES: NIL. Acknowledgements: NIL. Disclosure of Interests None Declared." @default.
• W4379522799 created "2023-06-07" @default.
• W4379522799 creator A5003814908 @default.
• W4379522799 creator A5004645087 @default.
• W4379522799 creator A5008041486 @default.
• W4379522799 creator A5008448004 @default.
• W4379522799 creator A5014114164 @default.
• W4379522799 creator A5014975422 @default.
• W4379522799 creator A5015504748 @default.
• W4379522799 creator A5015553608 @default.
• W4379522799 creator A5019220311 @default.
• W4379522799 creator A5019796937 @default.
• W4379522799 creator A5020805182 @default.
• W4379522799 creator A5022002558 @default.
• W4379522799 creator A5023364913 @default.
• W4379522799 creator A5024158466 @default.
• W4379522799 creator A5029797000 @default.
• W4379522799 creator A5032970295 @default.
• W4379522799 creator A5042929563 @default.
• W4379522799 creator A5048212121 @default.
• W4379522799 creator A5060722340 @default.
• W4379522799 creator A5062230891 @default.
• W4379522799 creator A5069186616 @default.
• W4379522799 creator A5076379466 @default.
• W4379522799 creator A5077553765 @default.
• W4379522799 creator A5081050956 @default.
• W4379522799 creator A5086170092 @default.
• W4379522799 date "2023-05-30" @default.
• W4379522799 modified "2023-10-18" @default.
• W4379522799 title "POS0219 COMPARISON OF METHOTREXATE AND AZATHIOPRINE AS THE FIRST STEROID-SPARING IMMUNOSUPPRESSIVE AGENT IN PATIENTS WITH TAKAYASU’S ARTERITIS" @default.
• W4379522799 doi "https://doi.org/10.1136/annrheumdis-2023-eular.6172" @default.
• W4379522799 hasPublicationYear "2023" @default.
• W4379522799 type Work @default.
• W4379522799 citedByCount "0" @default.
• W4379522799 crossrefType "journal-article" @default.
• W4379522799 hasAuthorship W4379522799A5003814908 @default.
• W4379522799 hasAuthorship W4379522799A5004645087 @default.
• W4379522799 hasAuthorship W4379522799A5008041486 @default.
• W4379522799 hasAuthorship W4379522799A5008448004 @default.
• W4379522799 hasAuthorship W4379522799A5014114164 @default.
• W4379522799 hasAuthorship W4379522799A5014975422 @default.
• W4379522799 hasAuthorship W4379522799A5015504748 @default.
• W4379522799 hasAuthorship W4379522799A5015553608 @default.
• W4379522799 hasAuthorship W4379522799A5019220311 @default.
• W4379522799 hasAuthorship W4379522799A5019796937 @default.
• W4379522799 hasAuthorship W4379522799A5020805182 @default.
• W4379522799 hasAuthorship W4379522799A5022002558 @default.
• W4379522799 hasAuthorship W4379522799A5023364913 @default.
• W4379522799 hasAuthorship W4379522799A5024158466 @default.
• W4379522799 hasAuthorship W4379522799A5029797000 @default.
• W4379522799 hasAuthorship W4379522799A5032970295 @default.
• W4379522799 hasAuthorship W4379522799A5042929563 @default.
• W4379522799 hasAuthorship W4379522799A5048212121 @default.
• W4379522799 hasAuthorship W4379522799A5060722340 @default.
• W4379522799 hasAuthorship W4379522799A5062230891 @default.
• W4379522799 hasAuthorship W4379522799A5069186616 @default.
• W4379522799 hasAuthorship W4379522799A5076379466 @default.
• W4379522799 hasAuthorship W4379522799A5077553765 @default.
• W4379522799 hasAuthorship W4379522799A5081050956 @default.
• W4379522799 hasAuthorship W4379522799A5086170092 @default.
• W4379522799 hasBestOaLocation W43795227991 @default.
• W4379522799 hasConcept C126322002 @default.
• W4379522799 hasConcept C141071460 @default.
• W4379522799 hasConcept C167135981 @default.
• W4379522799 hasConcept C2775905006 @default.
• W4379522799 hasConcept C2776694085 @default.
• W4379522799 hasConcept C2776715498 @default.
• W4379522799 hasConcept C2776755627 @default.
• W4379522799 hasConcept C2776760755 @default.
• W4379522799 hasConcept C2779134260 @default.
• W4379522799 hasConcept C2781059491 @default.
• W4379522799 hasConcept C71924100 @default.
• W4379522799 hasConcept C90924648 @default.
• W4379522799 hasConceptScore W4379522799C126322002 @default.
• W4379522799 hasConceptScore W4379522799C141071460 @default.
• W4379522799 hasConceptScore W4379522799C167135981 @default.
• W4379522799 hasConceptScore W4379522799C2775905006 @default.
• W4379522799 hasConceptScore W4379522799C2776694085 @default.
• W4379522799 hasConceptScore W4379522799C2776715498 @default.
• W4379522799 hasConceptScore W4379522799C2776755627 @default.
• W4379522799 hasConceptScore W4379522799C2776760755 @default.
• W4379522799 hasConceptScore W4379522799C2779134260 @default.
• W4379522799 hasConceptScore W4379522799C2781059491 @default.
• W4379522799 hasConceptScore W4379522799C71924100 @default.
• W4379522799 hasConceptScore W4379522799C90924648 @default.
• W4379522799 hasIssue "Suppl 1" @default.
• W4379522799 hasLocation W43795227991 @default.
• W4379522799 hasOpenAccess W4379522799 @default.
• W4379522799 hasPrimaryLocation W43795227991 @default.
• W4379522799 hasRelatedWork W1964181909 @default.
• W4379522799 hasRelatedWork W1973827734 @default.
• W4379522799 hasRelatedWork W1976895458 @default.
• W4379522799 hasRelatedWork W1996196496 @default.
• W4379522799 hasRelatedWork W2007266081 @default.
• W4379522799 hasRelatedWork W2008117421 @default.
• W4379522799 hasRelatedWork W2041700233 @default.
• W4379522799 hasRelatedWork W2044653550 @default.
• W4379522799 hasRelatedWork W2167388017 @default.

• next